DTx is expected to significantly influence and improve healthcare delivery and its consumption across the globe.
FREMONT, CA: With healthcare becoming increasingly digital, patients today are more empowered. As a result, digital health offerings have become the need of the hour to keep pace with the patients participating in their own care decisions. Digital health encompasses several platforms and systems that apply technological solutions to improve healthcare delivery. Digital therapeutics (DTx) is one category of digital health offerings that deliver evidence-based therapeutic interventions to prevent and manage the disease. Here is a comprehensive overview of DTx, its functions, and its applications in healthcare.
The DTx market value is about to reach USD 1.8 billion in 2020, which is estimated to reach USD 7.1 billion by 2025. DTx is a category of applications that help treat diseases through changes in patient behavior and remote monitoring to produce enhanced and long-term health results. These applications are tailored to achieve favorable outcomes, and they can encourage patients to adhere to a particular exercise routine or drug regimens. DTx applications are designed to target specific disease conditions, especially major chronic diseases like diabetes, cardiovascular conditions such as hypertension, and pulmonary diseases.
Services available under DTx complement and add on to the value of the conventional healthcare delivery system or have the ability to significantly replace the existing system. It helps patients with reminders for time and dosage of medication, thus enhancing their medication adherence. Diagnostic and therapeutic utilization of DTx can be counted under one class, while many firms are trying to transform behavioral interventions in digital formats. DTx depends exclusively on algorithms for its mechanism of action and algorithmic data management, making it seamless to generate, collate, and analyze the health data.
DTx can change what the healthcare industry offers, catering to both providers and patients both by selling digital services. An increasing number of healthcare facilities are taking a thoughtful approach to DTx. More rigorous testing is needed through randomized trials to attain reliable evidence on the safety and efficacy of DTx. Although DTx companies, stakeholders, and regulators are still in the primary stage, growing R and D investment will show the enormous impact of DTx very soon.